BioNTech pays $20M upfront for two monoclonal antibodies from China’s WuXi Biologics

BioN­Tech is pay­ing out $20 mil­lion up­front to an­oth­er Chi­nese part­ner in ex­change for the rights to de­vel­op two pre­clin­i­cal mon­o­clon­al an­ti­bod­ies, this time with CRD­MO WuXi Bi­o­log­ics.

The deal al­so in­cludes re­search, de­vel­op­ment, reg­u­la­to­ry and com­mer­cial mile­stone pay­ments, plus tiered roy­al­ties for the Shang­hai-based com­pa­ny, which will use its an­ti­body dis­cov­ery tech­nol­o­gy plat­forms to dis­cov­er the an­ti­bod­ies.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

OpenAI meets cancer care

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

Read More »